1. Home
  2. CNTX vs PBHC Comparison

CNTX vs PBHC Comparison

Compare CNTX & PBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • PBHC
  • Stock Information
  • Founded
  • CNTX 2015
  • PBHC 1859
  • Country
  • CNTX United States
  • PBHC United States
  • Employees
  • CNTX N/A
  • PBHC N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • PBHC Major Banks
  • Sector
  • CNTX Health Care
  • PBHC Finance
  • Exchange
  • CNTX Nasdaq
  • PBHC Nasdaq
  • Market Cap
  • CNTX 78.0M
  • PBHC 93.1M
  • IPO Year
  • CNTX 2021
  • PBHC N/A
  • Fundamental
  • Price
  • CNTX $0.84
  • PBHC $14.99
  • Analyst Decision
  • CNTX Strong Buy
  • PBHC
  • Analyst Count
  • CNTX 5
  • PBHC 0
  • Target Price
  • CNTX $5.50
  • PBHC N/A
  • AVG Volume (30 Days)
  • CNTX 197.0K
  • PBHC 3.0K
  • Earning Date
  • CNTX 08-06-2025
  • PBHC 08-05-2025
  • Dividend Yield
  • CNTX N/A
  • PBHC 2.67%
  • EPS Growth
  • CNTX N/A
  • PBHC N/A
  • EPS
  • CNTX N/A
  • PBHC 0.53
  • Revenue
  • CNTX N/A
  • PBHC $41,317,000.00
  • Revenue This Year
  • CNTX N/A
  • PBHC N/A
  • Revenue Next Year
  • CNTX N/A
  • PBHC N/A
  • P/E Ratio
  • CNTX N/A
  • PBHC $28.45
  • Revenue Growth
  • CNTX N/A
  • PBHC 1.46
  • 52 Week Low
  • CNTX $0.49
  • PBHC $13.71
  • 52 Week High
  • CNTX $2.75
  • PBHC $19.86
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 64.84
  • PBHC 47.50
  • Support Level
  • CNTX $0.82
  • PBHC $14.83
  • Resistance Level
  • CNTX $0.87
  • PBHC $15.55
  • Average True Range (ATR)
  • CNTX 0.07
  • PBHC 0.23
  • MACD
  • CNTX 0.01
  • PBHC -0.02
  • Stochastic Oscillator
  • CNTX 58.27
  • PBHC 14.16

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

Share on Social Networks: